Infections pose a serious health threat to individuals with chronic kidney disease (CKD) and end-stage renal disease (ESRD), representing a major cause of illness and mortality [2], [8]. Because the kidneys filter and eliminate many medications from the body, impaired renal function significantly changes how drugs are processed [2]. Proper antibiotic dosing is essential to effectively treat bacterial infections while preventing dangerous drug accumulation and toxicity [2].
The Complexities of Renal Dose Adjustments
Determining the correct antibiotic dose in patients with kidney disease is a clinical challenge [2]. Standard dosing guidelines are typically designed for patients with stable chronic kidney disease, and these rules may not translate accurately to individuals experiencing acute kidney injury (AKI) or critical illness [1]. For instance, research shows that AKI is frequently present upon hospital admission for conditions like pneumonia, urinary tract infections, and abdominal infections, but a significant portion of these acute kidney impairments resolve within the first 48 hours [1]. Automatically reducing antibiotic doses too early based on temporary kidney stress can lead to underdosing and reduced clinical response [1]. Clinicians must carefully evaluate renal function assessments and consider whether temporary conditions are skewing laboratory results [1], [2].
Patient-specific physical factors further complicate medication management. Variables such as abnormal fluid retention (edema), changes in blood protein levels (hypoproteinemia), and severe obesity alter how drugs distribute throughout the body [5]. Furthermore, patients undergoing specialized medical procedures like extracorporeal membrane oxygenation (ECMO) or various forms of dialysis require individualized dosing strategies because modern renal replacement therapies clear medications at varying rates [2], [5].
Risks of Toxicity and Adverse Reactions
When kidneys do not filter efficiently, antimicrobial medications can build up in the bloodstream, raising the risk of adverse side effects [2]. Broad-spectrum medications, such as carbapenems, require heightened vigilance [3]. Although generally effective against resistant pathogens, drugs like ertapenem carry a risk of neurotoxicity—including confusion or seizures—particularly in older adults and patients with pre-existing neurological conditions, low blood albumin, or underlying kidney impairment [3]. Monitoring patients for neurological changes during therapy is a critical component of safe prescribing [3].
Beyond direct toxicity, managing infections in this vulnerable population involves navigating high rates of multidrug-resistant organisms [8]. Patients with ESRD face unique immune alterations and frequent healthcare interactions that increase their exposure to resistant bacteria [8]. Combating these infections often requires a collaborative approach involving infectious disease specialists, strict infection prevention protocols, and careful antibiotic stewardship [8].
Optimizing Treatment and Patient Safety
Safe antibiotic therapy relies on striking a precise balance between clearing the infection and protecting delicate kidney function [2]. Healthcare providers must continuously review kidney function markers, patient weight, protein levels, and dialysis parameters to tailor safe medication regimens [2], [5]. Patients should always share a complete medical history—including any known kidney issues and current medications—with their healthcare team to support safe and effective treatment decisions.
Sources
- [1] Renal Dosing of Antibiotics: Are We Jumping the Gun?
- [2] Antibiotic Dosing in Chronic Kidney Disease and End-Stage Renal Disease: A Focus on Contemporary Challenges
- [3] Ertapenem-Associated Neurotoxicity in a Patient With Chronic Kidney Disease and Hypothyroidism: A Case Report
- [4] Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus-Clinical Practice Position Statement of the Polish Society of Nephrology
- [5] Optimization of antimicrobial treatment in sepsis
- [6] A study on the efficacy and safety of fosfomycin for the treatment of Multidrug-Resistant Enterobacterales urinary tract infection in North Indian type 2 diabetes mellitus patients
- [7] Effectiveness and Safety of Early Rhythm Control in Patients With Atrial Fibrillation and Chronic Kidney Disease
- [8] Prevention and Treatment of Multidrug-Resistant Organisms in End-Stage Renal Disease